<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Raloxifene</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00481</strong>&#160; (APRD00400)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A second generation selective estrogen receptor modulator (<span class="caps">SERM</span>) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00481/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00481/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00481.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00481.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00481.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00481.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00481.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00481">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>RAL</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Raloxifeno</td><td>Spanish</td><td>INN</td></tr><tr><td>Raloxifenum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Raloxifene Hydrochloride</strong>
          <div class="cas">82640-04-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000272/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000272/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: BKXVVCILCIUCLG-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 509.142756786</li>
              <li>Average Mass: 510.044</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000272">DBSALT000272</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Evista</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Keoxifene</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/bone-density-conservation-agents">Bone Density Conservation Agents</a></li>
<li><a href="/mesh/estrogen-antagonists">Estrogen Antagonists</a></li>
<li><a href="/mesh/selective-estrogen-receptor-modulators">Selective Estrogen Receptor Modulators</a></li>
<li><a href="/mesh/antihypocalcemic-agents">Antihypocalcemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>84449-90-1</td></tr><tr><th>Weight</th><td>Average: 473.583<br>Monoisotopic: 473.166079047</td></tr><tr><th>Chemical Formula</th><td>C<sub>28</sub>H<sub>27</sub>NO<sub>4</sub>S</td></tr><tr><th>InChI Key</th><td>GZUITABIAKMVPG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Phenylpropanoids and Polyketides</td></tr><tr><th>Class</th><td>Stilbenes</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Stilbenes</td></tr><tr><th>Alternative parents</th><td>Acetophenones; Benzothiophenes; Thiophene Carboxylic Acids and Derivatives; Phenol Ethers; Benzoyl Derivatives; Phenols and Derivatives; Alkyl Aryl Ethers; Piperidines; Tertiary Amines; Ketones; Enolates; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>acetophenone; benzothiophene; benzoyl; thiophene carboxylic acid or derivative; phenol ether; phenol derivative; alkyl aryl ether; piperidine; benzene; thiophene; ketone; tertiary amine; polyamine; ether; enolate; enol; amine; carbonyl group; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups  to a phenyl ring lead to stilbenoids.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention and treatment of osteoporosis in post-menopausal women, as well as prevention and treatment of corticosteroid-induced bone loss. Also for the reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis or have a high risk for developing breast cancer.</td></tr><tr><th>Pharmacodynamics</th><td>Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on breast and uterine tissue. Raloxifene differs chemically and pharmacologically from naturally occuring estrogens, synthetic steroidal and nonsteroidal compounds with estrogenic activity, and antiestrogens. Estrogens play an important role in the reproductive, skeletal, cardiovascular, and central nervous systems in women, and act principally by regulating gene expression. When estrogen binds to a ligand-binding domain of the estrogen receptor, biologic response is initiated as a result of a conformational change of the estrogen receptor, which leads to gene transcription through specific estrogen response elements of target gene promoters. The subsequent activation or repression of the target gene is mediated through 2 distinct transactivation domains of the receptor: AF-1 and AF-2. The estrogen receptor also mediates gene transcription using different response elements and other signalling pathways. The role of estrogen as a regulator of bone mass is well established. In postmenopausal women, the progressive loss of bone mass is related to decreased ovarian function and a reduction in the level of circulation estrogens. Estrogen also has favourable effects on blood cholesterol.</td></tr><tr><th>Mechanism of action</th><td>Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women, thus slowing the rate of bone loss. The maintenance of bone mass by raloxifene and estrogens is, in part, through the regulation of the gene-encoding transforming growth factor-&#946;3 (TGF-&#946;3), which is a bone matrix protein with antiosteoclastic properties. Raloxifene activates TGF-&#946;3 through pathways that are estrogen receptor-mediated but involve DNA sequences distinct from the estrogen response element. The drug also binds to the estrogen receptor and acts as an estrogen agonist in preosteoclastic cells, which results in the inhibtion of their proliferative capacity. This inhibition is thought to contribute to the drug's effect on bone resorption. Other mechanisms include the suppression of activity of the bone-resorbing cytokine interleukin-6 promoter activity. Raloxifene also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen. By competing with estrogens for the estrogen receptors in reproductive tissue, raloxifene prevents the transcriptional activation of genes containing the estrogen response element. As well, raloxifene inhibits the estradiol-dependent proliferation of MCF-7 human mammary tumor cells in vitro. The mechansim of action of raloxifene has not been fully determined, but evidence suggests that the drug's tissue-specific estrogen agonist or antagonist activity is related to the structural differences between the raloxifene-estrogen receptor complex (specifically the surface topography of AF-2) and the estrogen-estrogen receptor complex. Also, the existence of at least 2 estrogen receptors (ER&#945;, ER&#946;) may contribute to the tissue specificity of raloxifene. </td></tr><tr><th>Absorption</th><td>Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>2348 L/kg [oral administration of single doses ranging from 30 to 150 mg]</li>
</ul></td></tr><tr><th>Protein binding</th><td>95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, raloxifene undergoes extensive first-pass metabolism to the glucuronide conjugates: raloxifene-4'-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4'-diglucuronide. No other metabolites have been detected, providing strong evidence that raloxifene is not metabolized by cytochrome P450 pathways</p></td></tr><tr><th>Route of elimination</th><td>Raloxifene is primarily excreted in feces, and less than 0.2% is excreted unchanged in urine.</td></tr><tr><th>Half life</th><td>27.7</td></tr><tr><th>Clearance</th><td><ul>
	<li>44.1 L/kg&#8226;hr [Healthy Postmenopausal Woman with Single Dose]</li>
	<li>47.4 L/kg&#8226;hr [Healthy Postmenopausal Woman with Multiple Dose]</li>
	<li>Oral cl=44.1 L/kg&#8226;hr</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9865</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8661</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7751</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6231</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9366</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.634</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7897</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5198</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8986</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7617</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8222</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8487
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9433
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9587
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5287 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6322
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5779
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Eli lilly and co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.lilly.com">Eli Lilly &amp; Co.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lilly Del Caribe Inc.</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00269">Chlorotrianisene</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB01432">Cholestyramine</a></td><td>The resin decreases the effect of raloxifene</td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile Acid Sequestrants may decrease the absorption of Raloxifene. It would seem prudent to separate the doses of raloxifene and bile acid sequestrants by at least 2 hours. The manufacturer of raloxifene recommends against coadministration of these agents.1 The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. </td></tr><tr><td><a href="/drugs/DB00375">Colestipol</a></td><td>The resin decreases the effect of raloxifene</td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB04573">Estriol</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB04574">Estropipate</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Association not recommended</td></tr><tr><td><a href="/drugs/DB00451">Levothyroxine</a></td><td>Raloxifene decreases absorption of levothyroxine</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>Association not recommended</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>